Name | CCR6 antagonist 1 |
Description | CCR6 antagonist 1, a chemical compound acting as a CCR6 antagonist, effectively inhibits the CCL20/CCR6 axis. Its utility lies in research focused on autoimmune-mediated inflammatory diseases, including inflammatory bowel diseases (IBDs). |
In vitro | CCR6 antagonist 1 (50 μM, 3 h) blocks the CCL20-induced CD4+ T cell migration. CCR6 antagonist 1 (30 nM-300 μM, 20 min) inhibits miniGi recruitment to CCR6 induced by CCL20, and β-arrestin-1 recruitment to CCR6 and CCR5 by CCL20 and CCL5 (5 nM), respectively[1]. |
In vivo | CCR6 antagonist 1 (1 mg/kg, s.c., twice daily for 3 days) alleviates TNBS-induced inflammatory responses in mice. CCR6 antagonist 1 (1 mg/kg, s.c., twice, before and after zymosan treatment) shows anti-inflammatory effects in Zymosan-induced peritonitis mice[1]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 90 mg/mL (281.9 mM)
|
Keywords | CCR6 antagonist 1 | CCR6antagonist1 |
Inhibitors Related | AZD2098 | MLN-3897 TFA | Artemotil | CCR2 antagonist 5 | INCB-9471 | Maraviroc | BMS-817399 | PF-4136309 | Pirfenidone | Vercirnon |
Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Inhibitor Library | Immuno-Oncology Compound Library | Bioactive Compounds Library Max |